The integrin αvβ3 interacts with the arginine-glycine-aspartic acid (RGD) tripeptide recognition sequence of a variety of extracellular matrix proteins. Recent studies show that αvβ3 plays an important role in tumor-induced angiogenesis and tumor growth and that antagonists of αvβ3 inhibit angiogenic processes that include endothelial cell adhesion and migration. Consequently, we reasoned that an RGD-based peptidomimetic antagonist of αvβ3 might inhibit tumor angiogenesis and tumor growth in vivo. An RGD-peptidomimetic library was screened to identify antagonists of vitronectin binding to αvβ3, and the compounds chosen were modified to produce selective and potent inhibitors of αvβ3. One of these compounds, β-[[2-2-[[[3-[(aminoiminomethyl)amino]-phenyl]carbonyl]amino]acetyl]amino]-

3,5-dichlorobenzenepropanoic acid (SC-68448), inhibited vitronectin binding to both αvβ3 and the closely related platelet receptor, αIIbβ3, in a dose-responsive manner. SC-68448 inhibited vitronectin binding to αvβ3 (IC50, 1 nm) and fibrinogen binding to the platelet receptor αIIbβ3 (IC50, >100 nm), demonstrating that SC-68448 was 100-fold more potent as an inhibitor of αvβ3versus αIIbβ3. In cell-based studies, SC-68448 inhibited αvβ3-mediated endothelial cell proliferation in a dose-dependent manner but did not inhibit tumor cell proliferation, suggesting that effects on endothelial cell proliferation were not due to SC-68448-induced cytotoxicity. In accord with these results, SC-68448 inhibited angiogenesis in vivo in a basic fibroblast growth factor-induced rat corneal neovascularization model. A xenogeneic severe combined immune deficiency mouse/rat Leydig cell tumor model was developed for testing SC-68448 as an inhibitor of tumor growth in vivo. Rat Leydig cell tumors grew rapidly in severe combined immune deficiency mice and produced humoral hypercalcemia of malignancy. SC-68448 inhibited the growth of the tumors in mice by up to 80% and completely blocked the development of hypercalcemia. Together, these results demonstrate the feasibility of antitumor therapies based upon the development of nontoxic small molecule pharmacological antagonists of integrin αvβ3.

This content is only available via PDF.